Patents by Inventor Francisco Xavier Talamas

Francisco Xavier Talamas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selecting Clinical Trial Sites Based on Multiple Target Variables Using Machine Learning
    Publication number: 20240290442
    Abstract: Disclosed herein are methods for generating an automated method for determining or selecting one or more clinical trial sites for inclusion in a clinical trial. The method includes generating a predicted site enrollment (e.g., number of patients a site will enroll) and a predicted site default likelihood (e.g., how likely a site is to enroll zero patients or fewer patients than a predetermined threshold) for clinical trial sites by applying one or more machine learning models. The method further includes ranking the one or more clinical trial sites according to the predicted site enrollment and the predicted site default likelihood for the one or more clinical trial sites; and selecting top-ranked clinical trial sites.
    Type: Application
    Filed: September 9, 2022
    Publication date: August 29, 2024
    Inventors: Kaitlin Ann Hood, Francisco Xavier Talamas, Geoffrey Jerome Kip, Hans Roeland Geert Wim Verstraete
  • PREDICTING PERFORMANCE OF CLINICAL TRIAL FACILITATORS USING PATIENT CLAIMS AND HISTORICAL DATA
    Publication number: 20230124321
    Abstract: A clinical trial site evaluation system applies a machine learning technique to predict recruitment performance of a candidate clinical trial facilitator (such as a clinical trial site or a clinical trial investigator) for a clinical trial based on patient claims data or other data associated with the candidate clinical trial facilitator. In a training phase, a training system trains the machine learning model based on historical recruitment data associated with historical clinical trials and patient claims data (or other data) associated with the clinical trial facilitators associated with those trials. In a prediction phase, the machine learning model is applied to claims data (or other data) associated with candidate clinical trial facilitators to predict recruitment performance.
    Type: Application
    Filed: October 14, 2021
    Publication date: April 20, 2023
    Inventors: Hans Roeland Geert Wim Verstraete, Francisco Xavier Talamas, Nikolay Vladimirovitch Manyakov, Geoffrey Jerome Kip
  • Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators
    Publication number: 20180298026
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Inventors: Nidhl Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 10023589
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 17, 2018
    Assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • 4?-azido, 3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9708357
    Abstract: The present invention relates to the use of 3?-fluoro, 4?-azido nucleoside phosphoramidate prodrug derivatives of formula I wherein the symbols are as defined in the specification, to pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing such compounds for the treatment of HCV.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 18, 2017
    Assignee: Riboscience, LLC
    Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20160207936
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 21, 2016
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Ciara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 9255110
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: February 9, 2016
    Assignees: ROCHE PALO ALTO LLC, HOFFMANN-LA ROCHE INC.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20140369959
    Abstract: The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 18, 2014
    Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20140303149
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Heterocyclic antiviral compounds
    Patent number: 8734777
    Abstract: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: May 27, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Jim Li, Francisco Xavier Talamas
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    Publication number: 20130209397
    Abstract: Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: August 10, 2011
    Publication date: August 15, 2013
    Applicant: Roche Palo Alto LLC
    Inventors: Jim Li, Francisco Xavier Talamas
  • Quinoline inhibitors of hepatitis C virus polymerase
    Patent number: 8487103
    Abstract: Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: July 16, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas, Joshua Paul Gergely Taygerly
  • Heterocyclic antiviral compounds
    Patent number: 8329712
    Abstract: Compounds having the formula I wherein R1, R2, R3 and X are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Ryan Craig Schoenfeld, Francisco Xavier Talamas, Leanna Renee Staben
  • Heterocyclic antiviral compounds
    Patent number: 8273773
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: September 25, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Kenneth Albert Brameld, David Scott Carter, Elbert Chin, Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Eric Brian Sjogren, Francisco Xavier Talamas
  • Heterocyclic antiviral compounds
    Patent number: 8232271
    Abstract: Compounds having the formula I wherein R1, R2, R3a, R3b, R3c, R4, R5 and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: July 31, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Jim Li, Alfred Sui-Ting Lui, Kristen Lynn McCaleb, Francisco Xavier Talamas
  • Heterocyclic antiviral compounds
    Patent number: 8178547
    Abstract: Compounds having the formula I wherein A, R1, R2, R3, R4a, R4b, R4c, R5, R6, R7a, R7b, Ar1, Rc, Rd, Re, Rf, X, n and p are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: May 15, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Sandra Steiner, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • Heterocyclic antiviral compounds
    Patent number: 8168792
    Abstract: Compounds having the formula A-R wherein A is a heteroaryl and R is Ia, Ib or Ic and wherein A, R, R1, R2a, R2b, R2c, R3a, R3b, R4, R5, R6, Ra, Rb, Rc, Rd, X, X1, X2 and n are as are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: May 1, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Sarah C. Abbot, Alfred Sui-Ting Lui, Jim Li, Francisco Xavier Talamas
  • Heterocyclic antiviral compounds
    Patent number: 8158803
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4, R5a, R5b, R5c and R6 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: April 17, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Eun Kyung Lee, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • Heterocyclic antiviral compounds
    Patent number: 8158631
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4, and R5 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: April 17, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Elbert Chin, Javier de Vicente Fidalgo, Jim Li, Alfred Sui-Ting Lui, Kristen Lynn McCaleb, Ryan Craig Schoenfeld, Francisco Xavier Talamas
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20120015962
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Adreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai